SCI
UTHR icon

S&CO Inc’s United Therapeutics UTHR Stock Holding History

S&CO Inc’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$775K Hold
1,431
– – 0.04% 155
2026
Q1 		$848K Hold
1,431
– – 0.05% 146
2025
Q4 		$697K Hold
1,431
– – 0.04% 162
2025
Q3 		$599K Hold
1,431
– – 0.04% 167
2025
Q2 		$411K Hold
1,431
– – 0.03% 179
2025
Q1 		$441K Buy
+1,431
New +$490K 0.03% 174

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

S&CO Inc's UTHR Position: Q2 2026 in Review

S&CO Inc held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,431 shares worth $775K. The position accounts for 0.04% of the portfolio, ranked #155.

S&CO Inc first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $848K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • S&CO Inc held 1,431 shares of United Therapeutics worth $775K as of Q2 2026.
  • S&CO Inc left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.04% of S&CO Inc's portfolio in Q2 2026, its #155 holding.
  • S&CO Inc first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • S&CO Inc's United Therapeutics position peaked at $848K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.